Prevalence and risk factors for cancer of the uterine cervix among women living in Kinshasa, the Democratic Republic of the Congo : a cross-sectional study by Ali-Risasi, Catherine et al.
1 
 
Prevalence and risk factors for cancer of the uterine cervix among 1 
women living in Kinshasa, the Democratic Republic of the Congo: 2 
a cross-sectional study 3 
Catherine Ali-Risasi
1, 2§
, Kristien Verdonck
3
, Elizaveta Padalko
4,5
, Davy Vanden Broeck
6
, 4 
Marleen Praet
2
  5 
1
Laboratory of Anatomopathology, General Reference Hospital of Kinshasa, Kinshasa, 6 
Democratic Republic of the Congo  7 
2
N.Goormaghtigh Institute of Pathology, Ghent University Hospital, De Pintelaan 185, 8 
Ghent, Belgium  9 
3
Institute of Tropical Medicine, Nationalestraat 155,  Antwerp, Belgium  10 
4
Department of Microbiology, Clinical Chemistry and Immunology, Ghent University 11 
Hospital, De Pintelaan 185, Ghent, Belgium  12 
5
Faculty of Medicine and Life Sciences, Hasselt University, Agoralaan Building D, 13 
Diepenbeek, Belgium  14 
6
International Centre for Reproductive Health, Ghent University Hospital, De Pintelaan 15 
185, Ghent, Belgium  16 
§
Corresponding author  17 
Email addresses:  18 
CAR: cathymulumba@yahoo.fr  19 
2 
 
KV: tverdonck@itg.be  20 
EP: elizaveta.padalko@uzgent.be  21 
DVB: davy.vandenbroeck@ugent.be  22 
MP: marleen.praet@ugent.be  23 
 24 
Abstract  25 
Background  26 
Cancer of the uterine cervix is the leading cause of cancer-related death among women in Sub-27 
Saharan Africa, but information from the Democratic Republic of the Congo (DRC) is scarce. 28 
The study objectives were to: 1/ assess prevalence of (pre)cancerous cervical lesions in adult 29 
women in Kinshasa, 2/ identify associated socio-demographic and behavioural factors and 3/ 30 
describe human papillomavirus (HPV) types in cervical lesions.  31 
Methods  32 
A cross-sectional study was conducted in Kinshasa. Between 2006 and 2013, four groups of 33 
women were recruited. The first two groups were included at HIV screening centres. Group 1 34 
consisted of HIV-positive and group 2 of HIV-negative women. Group 3 was included in large 35 
hospitals and group  4 in primary health centres. Pap smears were studied by monolayer 36 
technique (Bethesda classification). Low- or high-grade squamous intraepithelial lesions or 37 
carcinoma were classified as LSIL+. HPV types were determined by INNO-LiPA
®
. Bivariate 38 
and multivariable analyses (logistic regression and generalised estimating equations (GEE)) 39 
were used to assess associations between explanatory variables and LSIL+.  40 
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Results  41 
LSIL+ lesions were found in 76 out of 1018 participants. The prevalence was 31.3% in group 1 42 
(n=131 HIV-positive women), 3.9% in group 2 (n=128 HIV-negative women), 3.9% in group 3 43 
(n=539) and 4.1% in group 4 (n=220). The following variables were included in the GEE 44 
model but did not reach statistical significance: history of abortion, ≥3 sexual partners and use 45 
of chemical products for vaginal care. In groups 3 and 4 where this information was available, 46 
the use of plants for vaginal care was associated with LSIL+ (adjusted OR 2.70 (95% 47 
confidence interval 1.04 - 7.01). The most common HPV types among HIV-positive women 48 
with ASCUS+ cytology (ASCUS or worse) were HPV68 (12 out of 50 samples tested), HPV35 49 
(12/50) , HPV52 (12/50) and HPV16 (10/50). Among women with negative/unknown HIV 50 
status, the most common types were HPV52 (10/40), HPV35, (6/40) and HPV18 (5/40).  51 
Conclusion  52 
LSIL+ lesions are frequent among women in Kinshasa. The use of plants for vaginal care 53 
deserves attention as a possible risk factor for LSIL+. In this setting, HPV16 is not the most 54 
frequent genotype in samples of LSIL+ lesions.  55 
Keywords: Cervical Intraepithelial Neoplasia – Human Papillomavirus– Risk Factors – 56 
Cross-Sectional Studies – Democratic Republic of the Congo  57 
  58 
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Background  59 
Cervical cancer constitutes a major health problem worldwide. It is responsible for 530,000 60 
new cases of cancer and causes 270,000 deaths each year [1,2]. Up to 80-85% of cervical 61 
cancer-related deaths occur in low-income countries [1,3]. In African women, it is the second 62 
most common cancer after breast cancer with an incidence rate of about 25 per 100,000 women 63 
per year. In Sub-Saharan Africa the incidence rate amounts to about 30-35, and here it is the 64 
most frequent cancer in women (for African data see [3-6]). It is expected, even on 65 
demographic grounds, that the burden of cervical cancer will further increase in Africa over the 66 
next years [7]. In contrast, in high-income countries such as the US and Europe the age-67 
standardized incidence rate is about 6 to 10 per 100,000 women per year [1,2]. Also the number 68 
of deaths from cervical cancer is nearly ten times lower in high-income countries [8,9]. 69 
Differences between low- and high-income countries have been related to differences in 70 
exposure to risk factors and adequacy of screening. The most important risk factor is human 71 
papillomavirus (HPV) infection. Several other factors have been found to increase the risk of 72 
cervical cancer, possibly through their relation with the risk of HPV infection: number of 73 
sexual partners, early sexual activity [10], parity [11], long-term use of oral contraceptives [12-74 
14], smoking [15] and HIV/AIDS [16-18].  75 
The link between cervical cancer and HPV infection has been well established [16,19-22]. 76 
From the more than 100 types of HPV described, about 40 are known to infect the genital tract 77 
and about 20 have been classified as oncogenic to humans [23-25]. Persistent infection with 78 
high-risk HPV has been considered as the necessary condition for malignant transformation of 79 
the cervical epithelium. In most studies, HPV16 and HPV18 are the predominant genotypes: 80 
they cause about 70% of precancerous lesions and cervical cancer [26]. In Sub-Saharan Africa 81 
however, other oncogenic genotypes have been reported [22,27-32].  82 
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In most Sub-Saharan countries, data on the prevalence and mortality of cervical cancer are 83 
either sparse or unavailable. Only 17% of African countries have a national programme and a 84 
specific budget for fighting cervical cancer. And where such a cervical cancer programme 85 
exists, the effective coverage may be low. In addition, those women at the highest risk of 86 
developing cervical cancer may have the most difficult access to care [33,34]. The prevalence 87 
of precancerous and cancerous lesions has been studied in a small number of women in the 88 
Democratic Republic of  the Congo (DRC) [35-40]. Some of these reports include the 89 
prevalence of HPV and/or cervical lesions in HIV-positive women  [35,40].  90 
Because of the high burden of cervical cancer in Sub-Saharan Africa, and presumably also in 91 
the DRC, the primary objectives of this study were to: 1/ evaluate the prevalence of 92 
(pre)cancerous lesions, 2/ identify associated socio-demographic and behavioural factors and 3/ 93 
describe HPV types present among women in Kinshasa. 94 
Results  95 
Characteristics of study participants  96 
The total number of participants was 1,018. One hundred thirty-one HIV-positive women were 97 
recruited at HIV screening centres (group 1); 128 HIV-negative women came from the same 98 
HIV screening centres (group 2); 539 women were recruited at large hospitals (group 3); and 99 
220 were referred through small health centres (group 4). The HIV status of the women in 100 
groups 3 and 4 was unknown. 101 
Table 1 shows the age and age-related characteristics of the participants. The mean age for all 102 
participants was 43.0 years (±12.8 standard deviation (SD)). The mean age of menarche was 103 
14.3 years (±1.9) and the age of the first sexual intercourse was 18.5 years (±3.9). Table 2 104 
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summarises the socio-demographical characteristics of the study population. About half of the 105 
women were married, with the highest percentage in group 3 (61.2%) and the lowest in group 2 106 
(20.3%). About one in ten women was widowed (18.0%), and one in four was single. 107 
Concerning pregnancies and parity, 44.0% of the women reported six or more pregnancies, 108 
29.8% responded to have six or more children and 60.7% reported to have had an abortion (not 109 
specified whether spontaneously or not).  110 
Behaviour-related characteristics of the study population are shown in table 3. About half of the 111 
participants reported to have had zero to two lifetime sexual partners. In groups 1 and 2 112 
(recruited at HIV screening centres), more women reported to have had three or more sexual 113 
partners (65.4% and 61.2% respectively). One out of five women declared to have used 114 
hormonal contraceptives (19.2%); no information is available on the duration of its use. One 115 
out of four women reported alcohol consumption, including regular as well as irregular use. 116 
About the same percentage (26.0%) reported to use chemical products for vaginal care. The 117 
women in groups 3 and 4 were also asked about the use of plants for vaginal care: 11.4% of the 118 
women confirmed the intravaginal application of plants or vegetable products. Although the 119 
structured interview did not include specific questions about the type of plants that were used, 120 
some interviewers took note of what some of the women reported. Terms that were mentioned 121 
repeatedly in the local language Lingala included: mbonzi-mbonzi (leaves of a tree), tangawisi 122 
(ginger), tomate (tomato), lumba-lumba (medicinal leaves) and ngai-ngai (sorrel).   123 
Prevalence of  low-grade squamous intraepithelial lesions or worse (LSIL+)  124 
In total, 76 of 1018 women were diagnosed with LSIL+ lesions (i.e. low- or high-grade 125 
squamous intraepithelial lesions (LSIL or HSIL) or invasive cancer, table 4). Among the HIV-126 
positive women of group 1, the prevalence of LSIL+ was 31.3% (95% confidence interval (CI): 127 
24.0% - 39.7%). Among the HIV-negative women recruited in the same clinics (group 2), the 128 
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LSIL+ prevalence was 3.9% (95% CI: 1.7% - 8.8%). Among the participants coming from the 129 
large hospitals (group 3), the prevalence was 3.9% (95%  CI: 2.6% - 5.9%) and among the 130 
women coming via smaller health centres (group 4),  4.1% (95% CI: 2.2% - 7.6%). Among the 131 
women with unknown or negative HIV status, lesions classified as ASCUS (atypical squamous 132 
cells of undetermined significance) or ASC-H (atypical squamous cells, cannot rule out high-133 
grade lesion) were more frequent than LSIL+ lesions (table 4).  134 
Socio-demographic factors and behaviour characteristics associated with LSIL+ lesions  135 
In each of the four groups, bivariate associations were assessed between all explanatory factors 136 
(age, socio-demographic and behaviour-related characteristics) and the presence of LSIL+ 137 
lesions. Crude odds ratios (ORs) are given in table 5. Explanatory factors with a P-value of 138 
<0.2 were included in a model of multiple logistic regression (one model per study group). The 139 
adjusted ORs are given in table 6. None of these associations reached statistical significance on 140 
multiple logistic regression.  141 
All participants were then analysed together using generalised estimating equations (GEE) to 142 
account for clustering within the study groups. Also in the GEE analysis, all factors with a P-143 
value <0.2 on bivariate evaluation were included in a multivariable model. The final GEE 144 
model (one model for all the study groups) included history of abortion (adjusted OR 1.60; 145 
95% CI 0.97 – 2.63), more than three sexual partners (adjusted OR 1.29; 95% CI 0.83 – 1.99) 146 
and use of chemical products for vaginal care (adjusted OR 0.65; 95% CI 0.37 – 1.14). Adding 147 
age to the model did not substantially change the ORs. None of the associations in this model 148 
reached statistical significance (table 6).  149 
The use of plants for vaginal care could only be evaluated in groups 3 and 4 because this 150 
information was not available for the women in the other groups. In a multiple logistic 151 
8 
 
regression model including the use of plants, alcohol consumption and having had more than 152 
three sexual partners, the adjusted OR for the association between the use of plants for vaginal 153 
care and the presence of LSIL+ lesions was 2.70 (95% CI 1.04 - 7.01; table 6). 154 
Determination of HPV DNA and HPV typing 155 
The following cytology results were classified as ASCUS+ and the corresponding samples 156 
were submitted for HPV typing: ASCUS, ASC-H, LSIL, HSIL or carcinoma. In the HIV-157 
positive group, 50 out of the 52 ASCUS+ samples contained HPV DNA. HPV16 was found in 158 
10 out of 50 samples, and HPV18 in 5 (table 7). Other genotypes that were frequently detected 159 
were HPV35 (n=12), HPV52 (n=12), HPV68 (n=12), HPV51 (n=10), and HPV31 (n=9). In the 160 
groups of women with negative or unknown HIV status, 50 samples were tested with INNO-161 
LiPA of which 40 contained detectable HPV DNA (table 7). Here, the most frequently detected 162 
genotype was HPV52 (n=10), HPV35 (n=6), HPV16 (n=3), HPV18 (n=5), HPV51(n=5), and 163 
HPV54 (n=5). In addition to the three samples in which HPV16 was detected through the 164 
INNO-LiPA test, there were three samples in which both the Abbot Real Time and the GenoID 165 
test indicated the presence of HPV16. 166 
In  groups 2, 3 and 4, 55% of samples which tested positive for HPV DNA contained one single 167 
HPV type. Two genotypes were found in 23% of the samples, three genotypes in 9%, four in 168 
7% and more than four in 7% of HPV-DNA positive samples. In the HIV-positive group (group 169 
1), a single HPV infection occurred only in 20.0% of the samples. Two genotypes were found 170 
in 38%, three in 9%, four in 16% and more than four in 18% of the samples.  171 
Discussion  172 
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The present study was performed to assess the prevalence of LSIL+ lesions and to identify 173 
associated factors in different groups of women in Kinshasa.. The prevalence of LSIL+ lesions 174 
ranged from approximately 4% in women with unknown or negative HIV status to 31% in 175 
HIV-positive women. We found an association between the practice of intravaginal insertion of 176 
plants and the presence of LSIL+. HPV types 16 and 18 which are known to cause cervical 177 
cancer in many countries worldwide appear to be less predominant in women in Kinshasa.  178 
The prevalence of LSIL+ lesions that we found in the current study in women with unknown or 179 
seronegative HIV status (4%) is consistent with the few studies previously performed in 180 
Kinshasa (3% and 5%) [35,36] and in Bukavu in the eastern part of the country (7%) [37]. 181 
Numbers of the same order of magnitude have been published in other Sub-Saharan countries. 182 
A prevalence between 4 and 10% was found in studies in Burkina-Faso, Nigeria, Tanzania, 183 
South Africa, Malawi and Kenya [29, 41-44,46, 47, 49-51]. Higher prevalences (16%) were 184 
reported in studies in the Central African Republic and Uganda [45,48]. These reports and our 185 
findings highlight the high and heterogeneous frequency of (pre)cancerous lesions in different 186 
countries of Sub-Saharan Africa. Furthermore, in our study, lesions classified as ASCUS and 187 
ASC-H were also frequent (more frequent than LISL+) among women with negative or 188 
unknown HIV status.  189 
Cervical cancer is known to be more frequent among HIV-positive women. In the DRC, it is 190 
estimated that 1.9% of the adult women are HIV infected, with differences between women 191 
living in urban areas (2.4%) and rural areas (1.0%) [52]. We found a prevalence of LSIL+ 192 
lesions of  31% in HIV-seropositive women. This finding is consistent with an earlier result 193 
(27%) described in a small group of seropositive women in Kinshasa [35]. Also in other Sub-194 
Saharan countries (pre)cancerous lesions were about five times more frequent in HIV-positive 195 
than in HIV-negative women [41,42,45,46,48,50,51,53].  196 
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Several demographic, economical and behavioural risk factors have been studied in relation to 197 
cervical cancer. Most of them may influence the risk of cancer through their effects on the risk 198 
of HIV and HPV infection. In the current study, we found a significant association between the 199 
intravaginal application of plant products and the presence of LSIL+ lesions. It is a frequent 200 
practice in Sub-Saharan Africa to use herbs, leaves and bark of trees to reduce vaginal 201 
lubrication and increase friction during sexual intercourse (dry sex) [54-59]. The perception is 202 
that dry sex increases sexual enjoyment. A study in the DRC revealed that one third of the 203 
women had used intra-vaginal substances at some time [55]. Another Congolese study looked 204 
into how specific plants are used and what the chemical and microbiological consequence of 205 
this traditional practice could be [60].  206 
Most of the studies about the vaginal use of plants have been done in relation to the risk of HIV 207 
infection. It has been hypothesised that differences in the vaginal environment may partially 208 
explain the different HIV transmission probabilities that are observed across populations [61]. 209 
Similar mechanisms may play a role in transmission and clearance of HPV [62-64]. The 210 
insertion of plant products and the increased friction during dry sex may alter the vaginal 211 
microbiota and cause traumatic microlesions in the vaginal wall facilitating the entry of HPV 212 
[62-64].   213 
The association between HPV infection and cervical cancer is well established, but the specific 214 
HPV genotypes that are involved in neoplasia differ across populations. The HPV types that 215 
have been most frequently linked to cervical cancer are: 16, 18, 31, 33, 45, 52 and 58  [53,65]. 216 
HPV16 and 18 are responsible for 70% of precancerous lesions and cervical cancer worldwide 217 
and consequently, these are the HPV types which the vaccine development has focused on. 218 
Nevertheless, our study suggests that HPV16 and 18 are less frequent (maximally 30% of 219 
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women with ASCUS+) and that HPV types 35,52 and 68 are more predominant than in other 220 
regions. Other studies in the DRC have also described specific patterns of HPV types [38,40].   221 
In other Sub-Saharan countries, the frequency of HPV16 and 18 varies. Some countries have 222 
reported patterns that resemble the situation in Europe and the United States [22,50,66,67], 223 
whereas in other countries, HPV types other than 16 and 18 appear to be more prominent 224 
[29,49,68,69].  225 
The DRC is a large country that is facing many complex problems at the same time. As a 226 
consequence, cervical cancer is not getting the attention that would be required for adequate 227 
disease control. Yet, the burden caused by cervical cancer in the DRC would justify a 228 
coordinated control strategy. This study together with a previous report illustrates that women 229 
in Kinshasa are willing to participate in prevention and control activities [70]. Interventions that 230 
could help to reduce the morbidity and mortality of cervical cancer include vaccination for 231 
HPV, systematic screening and early treatment. The effectiveness of such interventions may 232 
benefit from further research into the epidemiology of oncogenic HPV types and modifiable 233 
risk factors such as the use of plants for intimate care.   234 
Conclusion  235 
Our work illustrates that the prevalence of (pre)cancerous lesions in women from different 236 
districts in Kinshasa is approximately 4%. In HIV-positive women, the prevalence is about 237 
eight times higher. Traditional practices concerning vaginal hygiene may increase the risk of 238 
malignant transformation. More extensive studies, including rural areas, are needed to unravel 239 
the contribution of different HPV types in the development of cervical cancer.  240 
 241 
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Methods   242 
Study design, setting and participants  243 
We performed a cross-sectional study on the prevalence of precancerous and cancerous lesions 244 
of the uterine cervix in four groups of women in Kinshasa. The first two groups consisted of 245 
women who participated in a voluntary screening programme for HIV in the ACS/AMO-246 
CONGO centre (Action Communautaire contre le Sida/Avenir Meilleur pour les Orphelins du 247 
Sida au Congo) and in the Centre Hospitalier Monkole 3. Women who visited these centres for 248 
HIV screening and care between September 2006 and January 2007 were invited to participate 249 
in free cervical cancer screening. The first group (n=131) consisted of women who were found 250 
to be seropositive for HIV; the second group (n= 128) consisted of HIV-seronegative women. 251 
The diagnosis of HIV was based on two rapid tests (Determine
®
HIV-1/2 (Abbott) and 252 
OraQuick
®
HIV-1/2 (OraSure Technologies)) combined with one of the following serological 253 
tests: Vironostika
®
 Uni-Form II Plus O (BioMérieux), Enzygnost
®
 Anti-HIV ½ Plus (Siemens), 254 
or Inno-Lia HIVI/II Score (Inno-LIA
®
, Innogenetics). The third group (n= 539) consisted of 255 
women who consulted the gynaecology department of the Provincial Reference Hospital of 256 
Kinshasa (Hôpital Provincial Général de Référence de Kinshasa, HPGRK) and the Ngaliema 257 
hospital. Both hospitals are large state hospitals in the centre of the city. Data were collected 258 
from July to August 2009. At that time, a sensitisation campaign for free cervical screening was 259 
broadcast on television, posters advertising cervical cancer screening were shown at the 260 
hospitals, and a symposium on cervical cancer took place at the HPGRK. The participants of 261 
the fourth group (n= 220) were recruited via primary health care centres in the communities of 262 
Kimbanseke, Kisenso, Ndjili and Lemba, located in the poorer suburbs of the city. Data were 263 
collected from September 2012 to January 2013 after a campaign in local churches for free 264 
cervical cancer screening.  265 
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All women older than 17 who were willing to participate in the study and for whom a liquid-266 
based cytology (LBC) result was available were included in the analysis.  267 
Variables, data sources and measurement 268 
Cytology  269 
Cytology was the main outcome variable. Cervical smears were collected with Cervex Brush 270 
and conserved in ThinPrep solution for LBC and HPV typing. Samples were kept at 4°C. 271 
ThinPrep vials were transferred to the Pathology Laboratory of the University Hospital of 272 
Ghent, Belgium, for further analysis. The collected smears were independently read and 273 
interpreted by two pathologists. The pathologists were not aware of the HIV and HPV status at 274 
the time of reading the microscopy slides. In case of discrepancy, the slides were reread by both 275 
pathologists for a final interpretation. The cytology results were reported according to the 276 
Bethesda Classification 2001 of cervical pathology. Women with cytology results indicating 277 
LSIL (low-grade squamous intraepithelial lesion), HSIL (high-grade squamous intraepithelial 278 
lesion) and invasive carcinoma were considered to have precancerous or cancerous lesions and 279 
classified as LSIL+ (according to [71]). Women with ASCUS (atypical squamous of 280 
undetermined significance), ASC-H (atypical squamous, cannot rule out high-grade lesion) 281 
results or worse (ASCUS+) underwent HPV-DNA determination. Women with NILM 282 
(negative for intraepithelial lesion and malignancy) or inflammation were considered to be free 283 
of cancer.  284 
Determination of HPV DNA and HPV typing 285 
HPV typing was done in participants with ASCUS+ cytology results. Samples from women 286 
with ASCUS and ASC-H were included in the HPV evaluation as the European guidelines 287 
recommend to determine HPV DNA in these groups. INNO-LiPA HPV Genotyping Extra 288 
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(Innogenetics, Zwijnaarde, Belgium) was used for HPV typing. It is molecular technique based 289 
on the principle of reverse hybridisation designed to recognize fifteen high-risk HPV types (16, 290 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82), three probable high-risk HPV types 291 
(26, 53 and 66), seven low-risk HPV types (6, 11, 40, 43, 44, 54 and 70) and three non-292 
classified HPV types (69, 71 and 74).) The testing strategies varied across the study groups. In 293 
groups 1 and 2, INNO-LiPA Genotyping was done for all ASCUS+ cases. In groups 3 and 4, 294 
the INNO-LiPA test, due to its high cost, was only done if two other tests gave discordant 295 
results (Abbott Real Time High Risk HPV test (Abbott, Madison, USA) and Full Spectrum 296 
PCR HPV Amplification and Detection/Genotyping System (GenoID Molecular Diagnostics 297 
Laboratory, Budapest, Hungary)). We present all available INNO-LiPA results because this test 298 
detects many different HPV types [72]. Concordant Abbott and GenoID results for HPV16 and 299 
HPV18 are also reported. 300 
Socio-economic, gynaecological/medical and behaviour variables 301 
Socio-economic and behaviour characteristics that were studied in association with the 302 
presence or absence of LSIL+ were: age, age of menarche, age of first sexual contact, marital 303 
status, formal employment, life-time number of sexual partners, use of products for vaginal 304 
care (chemicals and products from plants), alcohol consumption (no alcohol versus any 305 
consumption), number of pregnancies, number of childbirths, and history of abortion (without 306 
discrimination between spontaneous or provoked). Concerning the practice of intravaginal 307 
application of plants, information was only available for groups 3 and 4.  308 
The variables “age”, “age of menarche” and “age of first sexual contact” follow a relatively 309 
normal distribution and are presented and analysed as continuous variables. The variables 310 
“number of sexual partners”, “number of pregnancies” and “number of deliveries” follow a 311 
clearly abnormal distribution and are presented and analysed as categorical variables. 312 
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Information about the socio-economic situation and behaviour characteristics was obtained 313 
through a structured interview by medical doctors. Interviewers followed a training session 314 
before the start of the study.  315 
Statistical analysis  316 
The prevalence of LSIL+ lesions with 95% confidence intervals (95% CI, Wilson score method 317 
without continuity correction) is reported for each of the four groups. Next, we used bivariate 318 
and multiple logistic regression to assess the association between socio-demographic and 319 
behaviour variables and the presence of LSIL+ lesions within each of the four groups. Finally, 320 
we analysed all participants together using generalized estimating equations (GEE) to account 321 
for clustering within the groups. The results of all logistic regression and GEE analyses are 322 
reported as odds ratios (OR) with 95% confidence intervals (95% CI). Data was missing for 323 
some participants in some of the explanatory variables; for each of the analyses, the number of 324 
included participants is given. We used Stata/IC 10.1 for data analysis.  325 
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Table 1. Age-related characteristics of the study population 
 Group 1 (n = 131) 
HIV screening centres 
HIV-positive women 
Group 2 (n = 128) 
HIV screening centres 
HIV-negative women 
Group 3 (n = 539) 
Hospitals 
HIV status unknown 
Group 4 (n = 220) 
Health centres 
HIV status unknown 
Total 
(n = 1018) 
Age      
   mean (years) ± SD 38.8 ± 9.1 29.4 ± 7.9 45.2 ± 11.0 48.0 ± 14.8  43.0 ± 12.8 
   range (years) 20 – 59 17 - 51 20 – 76 20 – 82  17 - 82 
   n with available data 131 128 537 216 1012 
Age of menarche      
   mean (years) ± SD 15.0 ± 1.9 14.5 ± 1.5 14.2 ± 1.9 14.5 ± 2.0  14.3 ± 1.9 
   range (years) 11 – 20 12- 17 10 – 21 10 - 20  10 - 21 
   n with available data 50 26 502 208 786 
Age of first sexual intercourse      
   mean (years) ± SD 17.2 ± 2.5  18.0  ± 3.2  18.8 ± 3.9  19.1 ± 4.5  18.5 ± 3.9  
   range (years) 12 – 25  12 – 32  10 – 36  12 – 32 10 – 36 
   n with available data 127 125 523 207 982 
 
n: number of participants with available data in each group; SD: standard deviation 
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Table 2. Socio-demographic characteristics of the study population 
 Group 1 (n = 131) 
HIV screening centres 
HIV-positive women 
Group 2 (n = 128) 
HIV screening centres 
HIV-negative women 
Group 3 (n = 539) 
Hospitals 
HIV status unknown 
Group 4 (n = 220) 
Health centres 
HIV status unknown 
Total 
(n = 1018) 
 n % n % n % n % n % 
Marital status 130  128  533  217  1008  
  married 43 (33.1) 26 (20.3) 326 (61.2) 120 (55.3) 515 (51.1) 
  single 39 (30.0) 95 (74.2) 76 (14.3) 33 (15.2) 243 (24.1) 
  widowed 34 (26.2) 4 (3.1) 92 (17.3) 51 (23.5) 181 (18.0) 
  divorced 14 (10.8) 3 (2.3) 39 (7.3) 13 (6.0) 69 (6.9) 
Formal employment 129  126  525  215  995  
  no 73 (56.6) 67 (53.2) 225 (42.9) 109 (50.7) 474 (47.6) 
  yes 56 (43.4) 59 (46.8) 300 (51.7) 106 (49.3) 521 (52.4) 
Number of pregnancies 128  126  517  219  990  
  0-2 29 (22.7) 87 (69.1) 131 (25.3) 53 (24.2) 300 (30.3) 
  3-5 42 (32.8) 28 (22.2) 124 (24.0) 60 (27.4) 254 (25.7) 
  6 or more 57 (44.5) 11 (8.7) 262 (50.7) 106 (48.4) 436 (44.0) 
Number of childbirths 128  126  520  218  992  
  0-2 48 (37.5) 100 (79.4) 190 (36.5) 70 (32.1) 408 (41.1) 
  3-5 41 (32.0) 20 (15.9) 161 (31.0) 66 (30.3) 288 (29.0) 
  6 or more 39 (30.5) 6 (4.8) 169 (32.5) 82 (37.6) 296 (29.8) 
Abortion 128  126  518  218  990  
  no 48 (37.5) 61 (48.4) 175 (33.8) 105 (48.2) 389 (39.3) 
  yes 80 (62.5) 65 (51.6) 343 (66.2) 113 (51.8) 601 (60.7) 
 
n: absolute number; %: percentage of participants in each study group and each category 
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Table 3. Behaviour-related characteristics of the study population 
 
 Group 1 (n = 131) 
HIV screening centres 
HIV-positive women 
Group 2 (n = 128) 
HIV screening centres 
HIV-negative women 
Group 3 (n = 539) 
Hospitals 
HIV status unknown 
Group 4 (n = 220) 
Health centres 
HIV status unknown 
Total 
(n = 1018) 
 n % n % n % n % n % 
Number of sexual partners 129  127  529  190  975  
   zero to two 50 (38.8) 44 (34.7) 304 (57.5) 132 (69.5) 530 (54.4) 
   three or more 79 (61.2) 83 (65.4) 225 (42.5) 58 (30.5) 445 (45.6) 
Use of hormonal contraception 131 131 128  539  171  969 969 
   no 105 (80.2) 118 (92.2) 421 (78.1) 139 (81.3) 783 (80.8) 
   yes 26 (19.8) 10 (7.8) 118 (21.9) 32 (18.7) 186 (19.2) 
Alcohol consumption 131  127  529  138  925 925 
   no 123 (93.9) 99 (78.0) 378 (71.5) 87 (63.0) 687 (74.3) 
   yes 8 (6.1) 28 (22.1) 151 (28.5) 51 (37.0) 238 (25.7) 
Use of plants for vaginal care     539  212  751 751 
   no     513 (95.2) 153 (72.2) 666 (88.6) 
   yes     26 (4.8) 59 (27.8) 85 (11.4) 
Use of chemical products for 
vaginal care 
131  128  539  151  949  
   no 98 (74.8) 92 (71.9) 445 (82.6) 67 (44.4) 702 (74.0) 
   yes 33 (25.2) 36 (28.1) 94 (17.4) 84 (55.6) 247 (26.0) 
 
n: absolute number; %: percentage of participants in each study group and each category 
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Table 4. Numbers and proportions of different lesions according to the Bethesda 2001 classification, per study group  
 
 Group 1 (n = 131) 
HIV screening centres 
HIV-positive women 
Group 2 (n = 128) 
HIV screening centres 
HIV-negative women 
Group 3 (n = 539) 
Hospitals 
HIV status unknown 
Group 4 (n = 220) 
Health centres 
HIV status unknown 
Total 
(n = 1018) 
 n (%) n (%) n (%) n  (%) 1018 (%) 
NILM 80 (61.1) 117 (91.4) 449 (83.3) 188 (85.5) 834 (81.9) 
ASCUS 9  (6.9) 5  (3.9) 46  (8.5) 19  (8.6) 79  (7.8) 
ASC-H 1  (0.8) 1  (0.8) 23  (4.3) 4  (1.8) 29  (2.9) 
LSIL 2  (1.5) 0  (0.0) 0  (0.0) 0  (0.0) 2  (0.2) 
HSIL 30 (22.9) 5  (3.9) 17  (3.2) 5  (2.3) 57  (5.6) 
Ca 9  (6.9) 0  (0.0) 4  (0.7) 4  (1.8) 17  (1.7) 
Subtotal: LSIL+ 41 (31.3) 5 (3.9) 21 (3.9) 9 (4.1) 76 (7.5) 
 
NILM: negative for intraepithelial lesion and malignancy 
ASCUS: atypical squamous cells of undetermined significance 
ASC-H: atypical squamous cells, cannot rule out high-grade lesion 
LSIL: low-grade squamous intraepithelial lesion 
HSIL: high-grade squamous intraepithelial lesion 
Ca: Carcinoma 
LSIL+: cytology findings compatible with (pre)cancerous lesions (includes low- and high-grade squamous intraepithelial lesions and carcinoma) 
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Table 5. Bivariate associations between socio-demographic and behavioural characteristics and presence of LSIL+ lesions, per study 
group 
 
  Group 1 (n = 131) 
HIV screening centres 
HIV-positive women 
Group 2 (n = 128) 
HIV screening centres 
HIV-negative women 
Group 3 (n = 539) 
Hospitals 
HIV status unknown 
Group 4 (n = 220) 
Health centres 
HIV status unknown 
    Crude OR 95% CI Crude OR 95% CI Crude OR 95% CI Crude OR 95% CI 
Age (in years) ‡   0.99 0.95 - 1.03 1.11 ** 1.00 -  1.24 1.02 0.98 - 1.07 1.02 0.97 -  1.06 
Age of menarche (in years) ‡   0.94 0.67 - 1.30 2.87 0.36 - 23.07 1.03 0.82 - 1.30 0.80 0.55 - 1.15 
Age of first sexual 
intercourse 
  0.89 * 0.76 - 1.05 1.09 0.86 - 1.38 1.01 0.90 - 1.13 0.84 * 0.68 - 1.06 
Marital status married 1.00   1.00 *   1.00   1.00   
  single 0.56 0.21 - 1.48 0.82 0.08 - 8.18 2.23 0.74 - 6.71 1.23 0.24 - 6.38 
  widowed 1.16 0.45 - 2.94 8.33 0.41 - 170.67 1.44 0.44 - 4.69 §   
  divorced 0.75 0.20 - 2.79 §   1.71 0.36 - 8.10 1.58 0.18 - 14.28 
Formal employment   0.75 0.35 - 1.61 1.74 0.28 - 10.79 1.92 * 0.73 - 5.03 0.28 * 0.06 - 1.38 
Number of pregnancies 0 - 2 1.00   1.00 **   1.00   1.00   
  3 - 5 1.31 0.47 - 3.70 1.96 0.14 - 18.04 1.06 0.33 - 3.38 0.28 0.03 - 2.80 
  6 or more 1.31 0.49 - 3.51 10.01 1.18 - 75.36 0.66 0.22 - 1.93 0.83 0.19 - 3.59 
Number of childbirths 0 - 2 1.00 *   1.00 **   1.00   1.00   
  3 - 5 1.08 0.96 - 5.77 8.65 1.34 - 55.65 0.31 0.15 - 1.70 0.70 0.11 - 4.31 
  6 or more 1.18 0.45 - 3.06 §   1.00 0.38 - 2.65 1.15 0.25 - 5.30 
Abortion   1.70 * 0.77 - 3.78 1.43 0.23 - 8.85 2.09 * 0.69 - 6.35 1.17 0.31 - 4.48 
Three or more lifetime sexual 
partners 
 1.26 0.58 - 2.74 2.18 0.24 - 20.10 2.27 * 0.92 - 5.57 0.91 0.17 - 4.82 
Hormonal contraception   1.21 0.49 - 3.00 3.17 0.32 - 31.40 1.12 0.40 - 3.12 §   
Alcohol consumption   0.30 0.04 - 2.49 2.46 0.39 - 15.51 1.57 0.64 - 3.87 4.62 * 0.86 - 24.75 
Plants for vaginal care   †   † *   3.59 * 0.99 – 13.05 2.15 0.56 – 8.31 
Chemicals for vaginal care   0.63 0.26 - 1.55 §   0.49 0.11 - 2.13 2.06 0.39 - 10.95 
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LSIL+: cytology findings compatible with (pre)cancerous lesions (includes low- and high-grade squamous intraepithelial lesions and carcinoma) 
OR: odds ratio; 95% CI: 95% confidence interval of the odds ratio 
‡ Age was treated as a continuous variable. Interpretation, e.g.in group 2: the odds of LSIL+ lesions increased with a factor 1.11 for each one-
year increase in age. 
** P-value of Wald, chi-squared or Fisher exact test < 0.05   
* P-value of Wald, chi-squared or Fisher exact test is not significant but is less than 0.2 
§ Odds ratio could not be calculated because there were cells without observations. 
† Data about use of plants for vaginal care were not available in groups 1 and 2. 
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Table 6. Multivariable evaluations of the association between explanatory variables and the presence of LSIL+ lesions 
 
Type of analysis Study groups included Number of observations * Explanatory variables included 
in the model 
Adjusted OR 95% CI 
Logistic regression 1 
(HIV screening centres 
HIV-positive women) 
124 Age of first sexual intercourse ‡ 0.86 0.72 – 1.02 
Number of pregnancies   
   0 – 2 1  
   3 – 5 0.95 0.31 – 2.86 
   6 or more 0.83 0.28 – 2.44 
Abortion 1.98 0.83 – 4.75 
Logistic regression 2 
(HIV screening centres 
HIV-negative women) 
123 Age ‡ 1.11 0.95 – 1.31 
Marital status   
   married 1  
   single 5.26 0.27 – 102.32 
   widowed 4.34 0.18 – 105.99 
   divorced §  
Number of pregnancies   
   0 – 2 1  
   3 – 5 1.15 0.07 – 18.34 
   6 or more 4.27 0.22 – 81.82 
Logistic regression 3 
(Hospitals 
HIV status unknown) 
502 Formal employment 2.08 0.74 – 5.88 
Abortion 1.65 0.53 – 5.14 
≥3 lifetime sexual partners 1.75 0.69 – 4.46 
Plants for vaginal care 2.85 0.75 – 10.82 
Logistic regression 4 
(Health centres 
HIV status unknown) 
203 Age of first sexual intercourse ‡ 0.86 0.68 – 1.07 
Formal employment 0.30 0.06 – 1.50 
GEE 1, 2 3 and 4 886 Abortion 1.60 0.97 – 2.63 
≥3 lifetime sexual partners 1.29 0.83 – 1.99 
Chemicals for vaginal care 0.65 0.37 – 1.14 
Logistic regression 3 and 4 643 Alcohol consumption 1.76 0.80 – 3.86 
≥3  lifetime sexual partners 1.58 0.72 – 3.46 
Plants for vaginal care 2.70 1.04 – 7.01 ** 
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LSIL+: cytology findings compatible with (pre)cancerous lesions (includes low- and high-grade squamous intraepithelial lesions and carcinoma) 
OR: odds ratio; 95% CI: 95% confidence interval of the odds ratio 
GEE: generalized estimating equations (population-averaged model; group variable: study group) 
‡ Age was treated as a continuous variable. 
§ Odds ratio could not be calculated because there were cells without observations. 
** P-value of Wald test < 0.05 
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Table 7. HPV genotyping results for women with ASCUS+ cytology 
 
HPV genotype Group 1 (HIV-positive women) Groups 2, 3 and 4 (women with unknown or negative HIV status) 
 Number of women with ASCUS+ = 52 Number of women with ASCUS+ = 133 
 Number of samples in which HPV DNA was detected = 50 Number of samples in which HPV DNA was detected = 40 
6 3 (6%) 0 (0%) 
11 2 (4%) 1 (3%) 
16  10 (20%) 3 (8%) * 
18 5 (10%) 5 (13%) 
31 9 (18%) 2 (5%) 
33 6 (12%) 4 (10%) 
35 12 (24%) 6 (15%) 
39 6 (12%) 4 (10%) 
40 1 (2%) 1 (3%) 
43 2 (4%) 0 (0%) 
44 5 (10%) 0 (0%) 
45 7 (14%) 2 (5%) 
51 10 (20%) 5 (13%) 
52 12 (24%) 10 (25%) 
53 5 (10%) 1 (3%) 
54 3 (6%) 5 (13%) 
56 6 (12%) 3 (8%) 
58 7 (14%) 0 (0%) 
59 2 (4%) 1 (3%) 
66 7 (14%) 4 (10%) 
68 12 (24%) 3 (8%) 
69 1 (2%) 1 (3%) 
70 5 (10%) 1 (3%) 
74 4 (8%) 4 (10%) 
82 0 (0%) 1 (3%) 
 
HPV: human papillomavirus 
ASCUS+ includes: atypical squamous cells of undetermined significance (ASCUS); atypical squamous cells; cannot rule out high-grade lesion 
(ASC-H); low- grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL) and carcinoma. 
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* In addition to the three samples in which HPV16 was detected through the INNO-LiPA test, there were three samples in which both the Abbot 
Real Time and the GenoID test indicated the presence of HPV16 
